Pharmacy decision-makers are constantly tasked with balancing budget, inventory, and therapeutic equivalency. When it comes to high-demand oral antibiotics, reliability and regulatory alignment are essential. That’s where Hikma’s Amoxicillin Tablets, USP 875 mg offer real value.
This product is a therapeutically equivalent alternative to AMOXIL®, the reference brand. Rated AB, Hikma’s formulation meets FDA standards for bioequivalence, giving hospital and outpatient pharmacies confidence in its interchangeability. It’s manufactured to meet high quality standards and is supplied in a convenient bottle of 100 tablets, offering strong support for both acute treatment regimens and routine stock requirements.
Product highlights for pharmacy teams:
- Strength: 875 mg
- Form: Tablet, film-coated and capsule-shaped
- Appearance: Scored on one side, imprinted WW951 on the other
- Packaging: Bottle of 100 tablets
- NDC: 0143-9285-01
Beyond its clinical consistency, Hikma’s Amoxicillin supports operational goals as well. With wide use in treating bacterial infections, amoxicillin continues to be a critical component of antimicrobial stewardship and formulary planning. Reliable availability, competitive pricing, and a solid AB rating make Hikma’s product a smart choice for health systems seeking sustainable, cost-conscious procurement.
